3D Quantitative Tumour Burden Analysis in Patients with Hepatocellular Carcinoma Before TACE: Comparing Single-lesion Vs. Multi-lesion Imaging Biomarkers As Predictors of Patient Survival

Overview

Journal Eur Radiol

Specialty Radiology

Date 2016 Jan 15

PMID 26762942

Citations 17

Authors

Florian N Fleckenstein

Rudiger E Schernthaner

Rafael Duran

Jae Ho Sohn

Sonia Sahu

Yan Zhao

Bernd Hamm

Bernhard Gebauer

MingDe Lin

Jean-Francois Geschwind

Julius Chapiro

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare the ability of single- vs. multi-lesion assessment on baseline MRI using 1D- and 3D-based measurements to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) before transarterial chemoembolization (TACE).

Methods: This retrospective analysis included 122 patients. A quantitative 3D analysis was performed on baseline MRI to calculate enhancing tumour volume (ETV [cm(3)]) and enhancing tumour burden (ETB [%]) (ratio between ETV [cm(3)] and liver volume). Furthermore, enhancing and overall tumour diameters were measured. Patients were stratified into two groups using thresholds derived from the BCLC staging system. Statistical analysis included Kaplan-Meier plots, uni- and multivariate cox proportional hazard ratios (HR) and concordances.

Results: All methods achieved good separation of the survival curves (p < 0.05). Multivariate analysis showed an HR of 5.2 (95 % CI 3.1-8.8, p < 0.001) for ETV [cm(3)] and HR 6.6 (95 % CI 3.7-11.5, p < 0.001) for ETB [%] vs. HR 2.6 (95 % CI 1.2-5.6, p = 0.012) for overall diameter and HR 3.0 (95 % CI 1.5-6.3, p = 0.003) for enhancing diameter. Concordances were highest for ETB [%], with no added predictive power for multi-lesion assessment (difference between concordances not significant).

Conclusion: 3D quantitative assessment is a stronger predictor of survival as compared to diameter-based measurements. Assessing multiple lesions provides no substantial improvement in predicting OS than evaluating the dominant lesion alone.

Key Points: • 3D quantitative tumour assessment on baseline MRI predicts survival in HCC patients. • 3D quantitative tumour assessment predicts survival better than any current radiological method. • Multiple lesion assessment provides no improvement than evaluating the dominant lesion alone. • Measuring enhancing tumour volume in proportion to liver volume reflects tumour burden.

Citing Articles

Deep learning-based 3D quantitative total tumor burden predicts early recurrence of BCLC A and B HCC after resection.

Wei H, Zheng T, Zhang X, Zheng C, Jiang D, Wu Y Eur Radiol. 2024; 35(1):127-139.

PMID: 39028376 PMC: 11632001. DOI: 10.1007/s00330-024-10941-y.

A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation.

Bartnik K, Krzyzinski M, Bartczak T, Korzeniowski K, Lamparski K, Wroblewski T Sci Rep. 2024; 14(1):14779.

PMID: 38926517 PMC: 11208561. DOI: 10.1038/s41598-024-65630-z.

Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters.

Mohseni A, Baghdadi A, Madani S, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A Abdom Radiol (NY). 2024; 49(8):2595-2605.

PMID: 38546828 DOI: 10.1007/s00261-024-04257-0.

Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation.

Yang S, Zhang Z, Su T, Chen Q, Wang H, Jin L Diagn Interv Radiol. 2023; 29(3):450-459.

PMID: 37154818 PMC: 10679614. DOI: 10.4274/dir.2023.222055.

Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.

Miszczuk M, Chapiro J, Do Minh D, van Breugel J, Smolka S, Rexha I Cardiovasc Intervent Radiol. 2022; 45(10):1494-1502.

PMID: 35941241 PMC: 9587516. DOI: 10.1007/s00270-022-03209-9.

References

Chapiro J, Lin M, Duran R, Schernthaner R, Geschwind J . Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther. 2014; 15(2):199-205. PMC: 4304995. DOI: 10.1586/14737140.2015.978861. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Kashkoush S, El Moghazy W, Kawahara T, Gala-Lopez B, Toso C, Kneteman N . Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant. 2014; 28(6):728-36. DOI: 10.1111/ctr.12373. View

Thiesse P, Ollivier L, Negrier S, Savary J, Pignard K, Lasset C . Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 1997; 15(12):3507-14. DOI: 10.1200/JCO.1997.15.12.3507. View

Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J . Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2015; 278(1):275-84. PMC: 4695977. DOI: 10.1148/radiol.2015142951. View

Yuen M, Cheng C, Lauder I, Lam S, Ooi C, Lai C . Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology. 2000; 31(2):330-5. DOI: 10.1002/hep.510310211. View

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

Lee H, Chapiro J, Schernthaner R, Duran R, Wang Z, Gorodetski B . How I do it: a practical database management system to assist clinical research teams with data collection, organization, and reporting. Acad Radiol. 2015; 22(4):527-33. PMC: 4355209. DOI: 10.1016/j.acra.2014.12.002. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

10.

Benson 3rd A, Abrams T, Ben-Josef E, Bloomston P, Botha J, Clary B . NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7(4):350-91. PMC: 4461147. DOI: 10.6004/jnccn.2009.0027. View

11.

Chapiro J, Duran R, Lin M, Schernthaner R, Wang Z, Gorodetski B . Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology. 2014; 275(2):438-47. PMC: 4409467. DOI: 10.1148/radiol.14141180. View

12.

. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28(3):751-5. DOI: 10.1002/hep.510280322. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Lewandowski R, Geschwind J, Liapi E, Salem R . Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011; 259(3):641-57. PMC: 3400295. DOI: 10.1148/radiol.11081489. View

15.

Lin M, Pellerin O, Bhagat N, Rao P, Loffroy R, Ardon R . Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial.... J Vasc Interv Radiol. 2012; 23(12):1629-37. PMC: 3579576. DOI: 10.1016/j.jvir.2012.08.028. View

16.

Llovet J, Schwartz M, Mazzaferro V . Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25(2):181-200. DOI: 10.1055/s-2005-871198. View

17.

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

18.

Chapiro J, Wood L, Lin M, Duran R, Cornish T, Lesage D . Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014; 273(3):746-58. PMC: 4263418. DOI: 10.1148/radiol.14140033. View

19.

Yau T, Tang V, Yao T, Fan S, Lo C, Poon R . Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146(7):1691-700.e3. DOI: 10.1053/j.gastro.2014.02.032. View

20.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View